Product Code: PHA1194
The Direct-to-Patient market is projected to grow at a CAGR of 6.1% by 2032.
“The Direct-to-Patient Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Industry Focus on Patient-Centricity Is Driving the Market Growth
The direct-to-patient and home trial support (DtP/HTS) strategy can provide priceless assistance to patients, regardless of whether they are getting a commercial therapy that has been approved or are taking part in a clinical trial. The DtP strategy has developed over the past ten years, with global adoption expanding dramatically in the last three years, fuelled by an industry focus on patient-centricity that is becoming more intense. This strategy provides considerable benefits for the patient as well as all other parties by enabling patients to obtain individualised care, cutting-edge or well-established therapies without leaving the comfort of their own homes. Technology has changed every part of our everyday life, which makes the world feel smaller than it has ever been.
Businesses in the medical, healthcare, and pharmaceutical industries have refrained from embracing social media for a variety of reasons. Corporations welcomed it, but pharmacists baulked because they thought it would present an excessive amount of legal risk. Even so, a few forerunners in the direct-to-patient sector have prepared the way for others. They have demonstrated that, in the quickly evolving healthcare environment of today, it is not only doable but also crucial. Tens of thousands of branding exercises are sent to patients in the medical field each day.
What Questions Should You Ask before Buying a Market Research Report?
- How is the direct-to-patient (DTP) market evolving?
- What is driving and restraining the direct-to-patient (DTP) market?
- How will each direct-to-patient (DTP) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each direct-to-patient (DTP) submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading direct-to-patient (DTP) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the direct-to-patient (DTP) projects for these leading companies?
- How will the industry evolve during the period between 2022 and 2032? What are the implications of direct-to-patient (DTP) projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the direct-to-patient (DTP) market?
- Where is the direct-to-patient (DTP) market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the direct-to-patient (DTP) market today, and over the next 10 years:
- Our 344- page report provides 155 tables and 165 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the direct-to-patient (DTP) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising direct-to-patient (DTP) prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Type
- Direct-to-Patient Marketing
- Direct-to-Patient Health Services
- Direct-to-Patient Clinical Trials
- Direct-to-Patient Logistics
Direct-to-Patient Marketing
- DTC Prescribed Drug Advertising
- Disease Awareness Campaigns
- Brand Promotion
- Healthcare Services Promotion
- Laboratory Testing Promotion
- Other Direct-to-Patient Marketing
Direct-to-Patient Health Services
- Tele Consultation
- Drug Prescription
- Medical Call Centers
- Telesampling
- Online Services
Direct-to-Patient Clinical Trials
- Tele Health Screening
- Investigational Medicinal Product (IMP)
- Patient Support Systems
- Other Clinical Trial Services
Direct-to-Patient Logistics
- Prescribed Medicine Delivery
- Pre-Clinical Supplies
- Clinical Trial Supplies
- Home Trial Support
- Test Samples Collection
- Rest All CSO Services
Therapeutics
- Cardiovascular Disease
- Respiratory Diseases
- Oncology
- Infectious Diseases
- Dermatology
- Other Therapeutics
Model
- Depot-to-Patient
- Site-to-Patient
- Hybrid Model
- Direct-From-Patient (DfP)
- Other DtP Models
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
MEA
- Turkey
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
Latin America
- Brazil
- Mexico
- Rest of Latin America
The report also includes profiles and for some of the leading companies in the Direct-to-Patient Market Report 2022-2032, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth:
- Access TeleCare
- Agnity Inc.
- AMD Global Telemedicine
- American Well
- Avel eCare
- Axs Health
- Babylon Health
- Citius Tech
- Dictum Health Inc.
- Doctor Anywhere
- Doctor on Demand
|
- Health Partners
- Health Tap
- HIMS
- Marken
- 20/20 NOW
- NURX
- Practo Technologies Pvt. Ltd.
- Specialists on call, Inc.
- Teladoc Health Inc.
- True pill
- Up Script Health
|
Overall world revenue for Direct-to-Patient (DTP) Market, 2022 to 2032 in terms of value the market will surpass US$40,746 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Direct-to-Patient Market Report 2022-2032 report help you?
In summary, our 340+ page report provides you with the following knowledge:
- Revenue forecasts to 2032 for Direct-to-Patient (DTP) Market, 2022 to 2032 Market, with forecasts for type, direct-to-patient marketing, direct-to-patient health services, clinical trials, direct-to-patient logistics, therapeutics, and model, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for five regional and 20 key national markets - See forecasts for the Direct-to-Patient (DTP) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 22 of the major companies involved in the Direct-to-Patient (DTP) Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Direct-to-Patient (DTP) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Table of Contents
1. Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Direct-To-Patient Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Increase in Social Media's Relevance
- 3.2.1.2 Direct-to-Patient Marketing Driven by Decentralization
- 3.2.1.3 Recognizing the Value of Direct-to-Patient
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Legal restrictions Are Impeding the Expansion of the DTP Market
- 3.2.2.2 Development of Digital Technology Projected to Boost Industry Growth
- 3.2.2.3 Booming Telehealth to Fuel Market Growth
- 3.2.3 Market Opportunities
- 3.2.3.1 DTP Services Are not Just for Delivering Medications
- 3.2.3.2 DTP Would be the Primary Point of Contact for Patient Support
- 3.2.3.3 DTP's Integration into Medical Universities, Clinics, and Hospitals
- 3.3 Supply Chain
- 3.4 COVID-19 Impact Analysis
- 3.4.1 COVID Impact Market Analysis (V-Shaped Recovery Scenario)
- 3.4.2 COVID Impact Market Analysis (W-Shaped Recovery Scenario)
- 3.4.3 COVID Impact Market Analysis (U-Shaped Recovery Scenario)
- 3.4.4 COVID Impact Market Analysis (L-Shaped Recovery Scenario)
- 3.5 Porter's Five Forces Analysis
- 3.5.1 Supplier Power
- 3.5.2 Buyer Power
- 3.5.3 Competitive Rivalry
- 3.5.4 Threat from Substitutes
- 3.5.5 Threat of New Entrants
- 3.6 PEST Analysis
- 3.6.1 Political Factors
- 3.6.2 Economic Factors
- 3.6.3 Social Factors
- 3.6.4 Technological Factors
4 Direct-to-Patient Market Analysis by Type
- 4.1 Key Findings
- 4.2 Type Segment: Market Attractiveness Index
- 4.3 Direct-to-Patient Marketing
- 4.4 Direct-to-Patient Health Services
- 4.5 Direct-to-Patient Clinical Trials
- 4.6 Direct-to-Patient Logistics
- 4.7 Direct-To-Patient Market by Type
5 Direct-To-Patient Market Analysis by Marketing
- 5.1 Key Findings
- 5.2 Marketing Segment: Market Attractiveness Index
- 5.3 DTC Prescribed Drug Advertising
- 5.4 Disease Awareness Campaigns
- 5.5 Brand Promotion
- 5.6 Healthcare Services Promotion
- 5.7 Laboratory Testing Promotion
- 5.8 Other Direct-to-Patient Marketing
- 5.9 Direct-to-Patient Market by Marketing
6 Direct-to-Patient Market Analysis by Direct-to-Patient Health Services
- 6.1 Key Findings
- 6.2 Direct-to-Patient Health Services Segment: Market Attractiveness Index
- 6.3 Tele Consultation
- 6.4 Drug Prescription
- 6.5 Medical Call Centers
- 6.6 Telesampling
- 6.7 Online Services
- 6.8 Direct-to-Patient Market by Health Service
7 Direct-to-Patient Market Analysis by Clinical Trials
- 7.1 Key Findings
- 7.2 Clinical Trials Segment: Market Attractiveness Index
- 7.3 Tele Health Screening
- 7.4 Investigational Medicinal Product (IMP)
- 7.5 Patient Support Systems
- 7.6 Other Clinical Trial Services
- 7.7 Direct-to-Patient Market by Clinical Trials
8 Direct-to-Patient Market Analysis by Direct-to-Patient Logistics
- 8.1 Key Findings
- 8.2 Direct-to-Patient Logistics Segment: Market Attractiveness Index
- 8.3 Prescribed Medicine Delivery
- 8.4 Pre-Clinical Supplies
- 8.5 Clinical Trial Supplies
- 8.6 Home Trial Support
- 8.7 Test Samples Collection
- 8.8 Direct-to-Patient Market by Logistics
9 Direct-to-Patient Market Analysis by Therapeutics
- 9.1 Key Findings
- 9.2 Therapeutics Segment: Market Attractiveness Index
- 9.3 Cardiovascular Diseases
- 9.4 Respiratory Diseases
- 9.5 Oncology
- 9.6 Infectious Diseases
- 9.7 Dermatology
- 9.8 Other Therapeutics
- 9.9 Direct-to-Patient Market by Therapeutics
10 Direct-to-Patient Market Analysis by Model
- 10.1 Key Findings
- 10.2 Model Segment: Market Attractiveness Index
- 10.3 Site-to-Patient
- 10.4 Hybrid Model
- 10.5 Direct-From-Patient (DfP)
- 10.6 Other DtP Models
- 10.7 Direct-to-Patient Market by Model
11 Direct-to-Patient Market Analysis by Region
- 11.1 Key Findings
- 11.2 Direct-to-Patient Market Attractiveness Index by Region
- 11.3 Direct-to-Patient Market Forecast
- 11.4 Direct-to-Patient Market by Region
12 North America Direct-To-Patient Market Analysis
- 12.1 Key Findings
- 12.2 Growing Desire for In-Home Care
- 12.3 Multinational DtP Company Presence in the Region
- 12.4 North America Direct-To-Patient Market Attractiveness Index by Region
- 12.5 Direct-to-Patient Market by Value
- 12.6 North America Direct-to-Patient Market by Marketing
- 12.7 North America Direct-to-Patient Market by Health Services
- 12.8 North America Direct-to-Patient Market by Clinical Trials
- 12.9 North America Direct-to-Patient Market by Logistics
- 12.10 North America Direct-to-Patient Market by Therapeutics
- 12.11 North America Direct-to-Patient Market by Model
- 12.12 North America Direct-to-Patient Market by Country
- 12.13 U.S. Direct-to-Patient Market Analysis
- 12.13.1 Rising Healthcare Costs Are Anticipated to Accelerate the Uptake of Telehealth
- 12.13.2 U.S. Laws for DTP Businesses
- 12.14 Canada Direct-to-Patient Market Analysis
- 12.14.1 Increasing Preference for Remote and Home Monitoring
13 Europe Direct-To-Patient Market Analysis
- 13.1 Key Findings
- 13.2 Significant Investment in Clinical Research Infrastructure
- 13.3 How DtP Supports Clinical Trial Innovation?
- 13.4 Europe Direct-to-Patient Market Attractiveness Index by Region
- 13.5 Europe Direct-to-Patient Market by Value
- 13.6 Europe Direct-to-Patient Market by Type
- 13.7 Europe Direct-to-Patient Market by Marketing
- 13.8 Europe Direct-to-Patient Market by Health Services
- 13.9 Europe Direct-to-Patient Market by Clinical Trials
- 13.10 Europe Direct-to-Patient Market by Logistics
- 13.11 Europe Direct-to-Patient Market by Therapeutics
- 13.12 Europe Direct-to-Patient Market by Model
- 13.13 Europe Direct-to-Patient Market by Country
- 13.14 Germany Direct-To-Patient Market Analysis
- 13.14.1 Germany's DTP Market Growing Due to Good Health Reimbursement Policies
- 13.14.2 Numerous Telemedicine Systems Are Now in Use
- 13.15 U.K. Direct-To-Patient Market Analysis
- 13.15.1 Hospital-based Care Trend Shifting to Home Care
- 13.15.2 Ageing Population Will Bring Opportunities for DTP
- 13.16 France Direct-To-Patient Market Analysis
- 13.16.1 Significant Fragmentation in the Direct-to-Patient Services Market
- 13.17 Italy Direct-to-Patient Market Analysis
- 13.17.1 Quality and Effectiveness of the Italian Healthcare System Can Occasionally Be Criticised
- 13.17.2 Laws Concerning the Delivery of DTP Services
- 13.18 Spain Direct-To-Patient Market Analysis
- 13.18.1 The Healthcare System in Spain is Among the Best in the World
- 13.19 Rest of Europe Direct-To-Patient Market Analysis
14 Asia-Pacific Direct-To-Patient Market Analysis
- 14.1 Key Findings
- 14.2 Growing Health Consumerism
- 14.3 A Shift in Stakeholder Confidence
- 14.4 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region
- 14.5 Asia Pacific Direct-to-Patient Market by Value
- 14.6 Asia Pacific Direct-to-Patient Market by Type
- 14.7 Asia Pacific Direct-to-Patient Market by Marketing
- 14.8 Asia Pacific Direct-to-Patient Market by Health Services
- 14.9 Asia Pacific Direct-to-Patient Market by Clinical Trials
- 14.10 Asia Pacific Direct-to-Patient Market by Logistics
- 14.11 Asia Pacific Direct-to-Patient Market by Therapeutics
- 14.12 Asia Pacific Direct-to-Patient Market by Model
- 14.13 Asia Pacific Direct-to-Patient Market by Country
- 14.14 China Direct-to-Patient Market Analysis
- 14.14.1 Government Made "Direct-To-Patients" Shipment of Investigational Drugs Mandatory
- 14.15 India Direct-to-Patient Market Analysis
- 14.15.1 Country's Healthcare System is Transitioning to the DtP Model
- 14.15.2 Telemedicine in India
- 14.16 Japan Direct-to-Patient Market Analysis
- 14.16.1 DtP Services Are Becoming More Popular in Japan
- 14.16.2 Close Patient Engagement is a Majorly Emerging Sector for Japanese Pharma
- 14.17 Australia Direct-to-Patient Market Analysis
- 14.17.1 Australian Government Offers Packages for Home Care Package (HCP)
- 14.17.2 Remarkable Growth of Australia's Market for Direct-To-Patient
- 14.18 South Korea Direct-to-Patient Market Analysis
- 14.19 Rest of Asia-Pacific Direct-to-Patient Market Analysis
15 Latin America Direct-To-Patient Market Analysis
- 15.1 Key Findings
- 15.2 Latin America Direct-to-Patient Market Attractiveness Index by Region
- 15.3 Latin America Direct-To-Patient Market by Value
- 15.4 Latin America Direct-To-Patient Market by Type
- 15.5 Latin America Direct-To-Patient Market by Marketing
- 15.6 Latin America Direct-To-Patient Market by Health Services
- 15.7 Latin America Direct-To-Patient Market by Clinical Trials
- 15.8 Latin America Direct-To-Patient Market by Logistics
- 15.9 Latin America Direct-To-Patient Market by Therapeutics
- 15.10 Latin America Direct-To-Patient Market by Model
- 15.11 Latin America Direct-To-Patient Market by Country
- 15.12 Brazil Direct-to-Patient Market Analysis
- 15.12.1 Government Policies for the DTP Industry
- 15.13 Mexico Direct-to-Patient Market Analysis
- 15.14 Rest of Latin America Direct-to-Patient Market Analysis
16 MEA Direct-To-Patient Market Analysis
- 16.1 Key Findings
- 16.2 MEA Direct-to-Patient Market Attractiveness Index by Region
- 16.3 MEA Direct-To-Patient Market by Value
- 16.4 MEA Direct-To-Patient Market by Type
- 16.5 MEA Direct-To-Patient Market by Marketing
- 16.6 MEA Direct-To-Patient Market by Health Services
- 16.7 MEA Direct-To-Patient Market by Clinical Trials
- 16.8 MEA Direct-To-Patient Market by Logistics
- 16.9 MEA Direct-To-Patient Market by Therapeutics
- 16.10 MEA Direct-To-Patient Market by Model
- 16.11 MEA Direct-To-Patient Market by Country
- 16.12 Saudi Arabia Direct-to-Patient Market Analysis
- 16.12.1 Saudi Arabia Government is Developing and Improving Healthcare Services Through a Transformation Plan
- 16.13 Turkey Direct-to-Patient Market Analysis
- 16.13.1 Direct To Patient Has a Large Distribution Network that Reaches All Regions of Turkey
- 16.13.2 Turkey's Family Medicine Reform Will Boost Demand for DtP Services in Nearing Future
- 16.14 UAE Direct-to-Patient Market Analysis
- 16.14.1 Rise in Healthcare Demand in the United Arab Emirates
- 16.14.2 UAE is Moving Toward DtP and Telehealth Models
- 16.15 South Africa Direct-to-Patient Market Analysis
- 16.15.1 Professional Training is Required for DtP Service Providers
- 16.15.2 Patient's Cultural and Family Context at Home Must Include Professional DTP
- 16.16 Rest of MEA Direct-to-Patient Market Analysis
- 16.16.1 Start-Ups in the Nation Could Destabilise the DTP Market
17 Competitive Landscape
- 17.1 Key Business Strategy Analysis- Agreement
- 17.2 Key Business Strategy Analysis- Contract
- 17.3 Key Business Strategy Analysis- Expansion
- 17.4 Key Business Strategy Analysis- Partnership
- 17.5 Key Business Strategy Analysis- Launch
18 Company Profiles
- 18.1 Access TeleCare
- 18.1.1 Company Snapshot
- 18.1.2 Company Overview
- 18.1.3 Product Benchmarking
- 18.1.4 Strategic Outlook
- 18.2 Agnity Inc.
- 18.2.1 Company Snapshot
- 18.2.2 Company Overview
- 18.2.3 Product Benchmarking
- 18.2.4 Strategic Outlook
- 18.3 AMD Global Telemedicine
- 18.3.1 Company Snapshot
- 18.3.2 Company Overview
- 18.3.3 Product Benchmarking
- 18.3.4 Strategic Outlook
- 18.4 American Well
- 18.4.1 Company Snapshot
- 18.4.2 Company Overview
- 18.4.3 Financial Analysis
- 18.4.3.1 Net Revenue, 2018-2021
- 18.4.3.2 Operating Income, 2018-2021
- 18.4.3.3 Research & Development Expenses, 2018-2021
- 18.4.4 Product Benchmarking
- 18.4.5 Strategic Outlook
- 18.5 Avel eCare
- 18.5.1 Company Snapshot
- 18.5.2 Company Overview
- 18.5.3 Product Benchmarking
- 18.5.4 Strategic Outlook
- 18.6 Axs Health
- 18.6.1 Company Snapshot
- 18.6.2 Company Overview
- 18.6.3 Product Benchmarking
- 18.6.4 Strategic Outlook
- 18.7 Babylon Health
- 18.7.1 Company Snapshot
- 18.7.2 Company Overview
- 18.7.2.1 Net Revenue, 2019-2021
- 18.7.2.2 Operating Income, 2019-2021
- 18.7.2.3 R&D Expenses, 2019-2021
- 18.7.3 Product Benchmarking
- 18.7.4 Strategic Outlook
- 18.8 Citius Tech
- 18.8.1 Company Snapshot
- 18.8.2 Company Overview
- 18.8.3 Product Benchmarking
- 18.8.4 Strategic Outlook
- 18.9 Dictum Health Inc.
- 18.9.1 Company Snapshot
- 18.9.2 Company Overview
- 18.9.3 Product Benchmarking
- 18.9.4 Strategic Outlook
- 18.10 Doctor Anywhere
- 18.10.1 Company Snapshot
- 18.10.2 Company Overview
- 18.10.3 Product Benchmarking
- 18.10.4 Strategic Outlook
- 18.11 Doctor on Demand
- 18.11.1 Company Snapshot
- 18.11.2 Company Overview
- 18.11.3 Product Benchmarking
- 18.11.4 Strategic Outlook
- 18.12 Health Partners
- 18.12.1 Company Snapshot
- 18.12.2 Company Overview
- 18.12.3 Financial Analysis
- 18.12.3.1 Net Revenue, 2018-2020
- 18.12.3.2 Operating Income, 2018-2020
- 18.12.4 Product Benchmarking
- 18.12.5 Strategic Outlook
- 18.13 Health Tap
- 18.13.1 Company Snapshot
- 18.13.2 Company Overview
- 18.13.3 Product Benchmarking
- 18.13.4 Strategic Outlook
- 18.14 HIMS
- 18.14.1 Company Snapshot
- 18.14.2 Company Overview
- 18.14.3 Financial Analysis
- 18.14.3.1 Net Revenue, 2019-2021
- 18.14.3.2 Operating Income, 2019-2021
- 18.14.4 Product Benchmarking
- 18.14.5 Strategic Outlook
- 18.15 Marken
- 18.15.1 Company Snapshot
- 18.15.2 Company Overview
- 18.15.3 Product Benchmarking
- 18.15.4 Strategic Outlook
- 18.16 20/20 NOW
- 18.16.1 Company Snapshot
- 18.16.2 Company Overview
- 18.16.3 Product Benchmarking
- 18.16.4 Strategic Outlook
- 18.17 NURX
- 18.17.1 Company Snapshot
- 18.17.2 Company Overview
- 18.17.3 Product Benchmarking
- 18.17.4 Strategic Outlook
- 18.18 Practo Technologies Pvt. Ltd
- 18.18.1 Company Snapshot
- 18.18.2 Company Overview
- 18.18.3 Product Benchmarking
- 18.18.4 Strategic Outlook
- 18.19 Specialists on call, Inc
- 18.19.1 Company Snapshot
- 18.19.2 Company Overview
- 18.19.3 Financial Analysis
- 18.19.3.1 Net Revenue, 2019-2021
- 18.19.3.2 Research & Development Expense, 2019-2021
- 18.19.4 Product Benchmarking
- 18.19.5 Strategic Outlook
- 18.20 Teladoc Health Inc
- 18.20.1 Company Snapshot
- 18.20.2 Company Overview
- 18.20.3 Financial Analysis
- 18.20.3.1 Net Revenue, 2017-2021
- 18.20.3.2 Operating Income, 2017-2021
- 18.20.3.3 Research & Development Expenses, 2017-2021
- 18.20.4 Product Benchmarking
- 18.20.5 Strategic Outlook
- 18.21 True pill
- 18.21.1 Company Snapshot
- 18.21.2 Company Overview
- 18.21.3 Product Benchmarking
- 18.21.4 Strategic Outlook
- 18.22 Up Script Health
- 18.22.1 Company Snapshot
- 18.22.2 Company Overview
- 18.22.3 Product Benchmarking
- 18.22.4 Strategic Outlook
19 Conclusion and Recommendations
- 19.1 Concluding Remarks from
- 19.2 Recommendations for Market Players